Engineering T cells to improve treatment for ovarian cancer
Engineering T cells to overcome inhibitory receptor signals that limit the efficacy of adoptive cell therapy against ovarian cancer
['FUNDING_OTHER'] · UNIVERSITY OF VIRGINIA · NIH-11076712
This study is looking at ways to make T cell therapies better for people with ovarian cancer by tweaking the T cells so they can find and fight cancer cells more effectively while being gentle on healthy cells.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF VIRGINIA (nih funded) |
| Locations | 1 site (CHARLOTTESVILLE, UNITED STATES) |
| Trial ID | NIH-11076712 on ClinicalTrials.gov |
What this research studies
This research focuses on enhancing the effectiveness of T cell therapies for ovarian cancer by engineering T cells to target specific proteins found in tumors. The approach involves modifying T cells to express high-affinity receptors that can recognize and attack ovarian cancer cells while minimizing damage to healthy tissues. The study also investigates how the tumor microenvironment affects the persistence and function of these engineered T cells, aiming to overcome inhibitory signals that limit their effectiveness.
Who could benefit from this research
Good fit: Ideal candidates for this research are women diagnosed with ovarian cancer who may benefit from innovative immunotherapy approaches.
Not a fit: Patients with ovarian cancer who do not express the targeted proteins or have advanced disease stages may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and targeted treatments for ovarian cancer, potentially improving survival rates and quality of life for patients.
How similar studies have performed: Previous research has shown promise in using engineered T cells for cancer treatment, indicating potential success for this novel approach.
Where this research is happening
CHARLOTTESVILLE, UNITED STATES
- UNIVERSITY OF VIRGINIA — CHARLOTTESVILLE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: ANDERSON, KRISTIN GAIL — UNIVERSITY OF VIRGINIA
- Study coordinator: ANDERSON, KRISTIN GAIL
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: anti-cancer